Tscan Therapeutics Valuation
| TCRX Stock | USD 2.64 0.06 2.33% |
Based on Macroaxis valuation methodology, the company appears to be fairly valued. Tscan Therapeutics has a current Real Value of $2.61 per share. The regular price of the company is $2.64. Our model measures the value of Tscan Therapeutics from inspecting the company fundamentals such as Return On Equity of -0.56, shares owned by insiders of 0.82 %, and Current Valuation of (34.98 M) as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Tscan Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Tscan Therapeutics is based on 3 months time horizon. Increasing Tscan Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Tscan Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tscan Stock. However, Tscan Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.64 | Real 2.61 | Hype 2.64 | Naive 2.53 |
The intrinsic value of Tscan Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tscan Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tscan Therapeutics helps investors to forecast how Tscan stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tscan Therapeutics more accurately as focusing exclusively on Tscan Therapeutics' fundamentals will not take into account other important factors: Tscan Therapeutics Total Value Analysis
Tscan Therapeutics is at this time projected to have valuation of (34.98 M) with market capitalization of 145.78 M, debt of 92.43 M, and cash on hands of 125.6 M. The negative valuation of Tscan Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Tscan Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(34.98 M) | 145.78 M | 92.43 M | 125.6 M |
Tscan Therapeutics Investor Information
About 87.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.64. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tscan Therapeutics recorded a loss per share of 0.95. The entity last dividend was issued on the 13th of September 1970. Based on the key indicators related to Tscan Therapeutics' liquidity, profitability, solvency, and operating efficiency, Tscan Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Tscan Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Tscan Therapeutics has an asset utilization ratio of 7.73 percent. This suggests that the Company is making $0.0773 for each dollar of assets. An increasing asset utilization means that Tscan Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Tscan Therapeutics Ownership Allocation
Tscan Therapeutics shows a total of 52.23 Million outstanding shares. The majority of Tscan Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tscan Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tscan Therapeutics. Please pay attention to any change in the institutional holdings of Tscan Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Tscan Therapeutics Profitability Analysis
The company reported the previous year's revenue of 21.05 M. Net Loss for the year was (89.22 M) with loss before overhead, payroll, taxes, and interest of (91.04 M).About Tscan Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Tscan Therapeutics. We calculate exposure to Tscan Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tscan Therapeutics's related companies.TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Tscan Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people.
Tscan Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 65.6 M |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.